🔎 Trials Near Me

Gara Jalqabaatti › Myeloma Baay’ee › Alabama

Qorannoo klinikaalii Myeloma Baay’ee Alabama keessatti

Qorannoo 22 Myeloma Baay’ee f Alabama keessatti hirmaatuu jiru.

Magaalota Alabama keessatti

Takkalaa qorannoo (Ingiliffa)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • University of Alabama At Birmingham Hospital, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Alabama Oncology, Birmingham
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07518186

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • University of Alabama Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT04634552

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

  • University of Alabama at Birmingham Hospital, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT02693535

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06297226

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  • Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06980480

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT06988488

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05850234

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Clearview Cancer Institute, Huntsville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT07284758

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ado-2026 · NCT06121843

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT06974786

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Bit-2026 · NCT06153251

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT07333261

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Mud-2025 · NCT04991103

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

  • Kirklin Clinic of UAB Hospital, Birmingham
Namoota walitti qabaa jira
Umuriin 60 fi ol · Saalaa hunda · Haaromfame 24-Mud-2025 · NCT05642884

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

  • Kirklin Clinic of UAB Hospital, Birmingham
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 08-Mud-2025 · NCT05556928

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • University of Alabama at Birmingham, Birmingham
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2025 · NCT05722418

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

  • UAB Comprehensive Cancer Center, Birmingham
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Ful-2025 · NCT05372354

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.